About Okomera
Okomera is a company based in Paris (France) founded in 2020 by Aimee Wessel, Sandra Jernstrom, Raphael Tomasi, and Charles Baroud. Okomera has raised $11.17 million across 1 funding round from investors including Polytechnique Ventures, Berkeley SkyDeck Fund and Resonance. Okomera offers products and services including 3D Organoid Screening Platform and AI Analysis Platform. Okomera operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Paris, France
- Founders Aimee Wessel, Sandra Jernstrom, Raphael Tomasi, Charles Baroud
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.17 M (USD)
in 1 rounds
-
Latest Funding Round
$11.17 M (USD), Seed
Dec 20, 2023
-
Investors
Polytechnique Ventures
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Okomera
Okomera offers a comprehensive portfolio of products and services, including 3D Organoid Screening Platform and AI Analysis Platform.
Automates high-throughput screening of organoids for cancer research
Provides end-to-end AI for organoid data processing in drug testing
Funding Insights of Okomera
Okomera has successfully raised a total of $11.17M through 1 strategic funding round. The most recent funding activity was a Seed round of $11.17 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Okomera
Okomera has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Polytechnique Ventures, Berkeley SkyDeck Fund and Resonance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A seed fund is managed to support startups from Ecole Polytechnique ecosystem.
|
Locked | Locked | Locked | |
|
Investments are directed toward early-stage tech startups by Resonance.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Okomera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Okomera
Investment portfolio details for Okomera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Okomera
Detailed financials for Okomera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Okomera Comparisons
Peer comparison for Okomera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Okomera
Okomera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Okomera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Okomera
Complete news archive for Okomera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Okomera
Okomera was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Okomera is headquartered in Paris, France.
Aimee Wessel is the current CEO of Okomera. They have also founded this company.
Okomera is a funded company, having raised a total of $11.17M across 1 funding round to date.
Okomera was founded in 2020 in Paris, France, within the biotechnology sector. A device employing microfluidic chips for in vitro cancer testing is developed. Proprietary technology is utilized for personalized treatments and evaluation of cancer cells in 3D spheroids. Tumor biopsies are analyzed through this method, supporting research in oncology applications.
Okomera's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.
Okomera offers 3D Organoid Screening Platform and AI Analysis Platform.
Okomera has 4 investors. Key investors include Polytechnique Ventures, Berkeley SkyDeck Fund, Resonance, and Otium Capital.